Clinical trials: Glucagon
Obesity
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy.
- Trial name
- NCT07633639
- Testing
- LSG-Semaglutide group, LSG-Mazdutide group, LSG-Tirzepatide group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- China-Japan Friendship Hospital
Angina Pectoris
Cardioprotective Effects of GLP-1 and Their Mechanisms
Ischaemic heart disease is the most common cause of death in the UK. Glucagon-like peptide-1 (GLP-1) has been demonstrated to protect the heart when it is deprived of blood supply (ischaemia).
- Trial name
- NCT02128022
- Testing
- GLP-1 (7-36) amide, Glibenclamide
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Type 2 Diabetes, Blod Pressure
Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus
Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected.
- Conditions
- Type 2 Diabetes, Blod Pressure, Glucagon-like Peptide-1, Human Physiology
- Trial name
- NCT01689051
- Testing
- human glucagon-like peptide 1 (7-36)amide, human glucagon-like peptide 1 (9-36)amide
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 1 Diabetes, Hypoglycemia
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
The purpose of this study is to determine whether ZT-01 increases the glucagon response to hypoglycemia in type 1 diabetes (T1D).
- Trial name
- NCT05007977
- Testing
- ZT-01 low dose, ZT-01 high dose
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Zucara Therapeutics Inc.
T2DM, Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT05680129
- Testing
- Ecnoglutide high dosage, Ecnoglutide low dosage, Dulaglutide
- Where
- China
- Volunteers
- 623 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
This study aims to assess the effect of using Glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists on gastric emptying on surgical patients and whether specific guidelines need to be established for these patients.
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia
- Trial name
- NCT07140289
- Testing
- Ultrasound of gastric contents
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wael Saasouh, MD
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be…
- Trial name
- NCT02806960
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Gallbladder
The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying
The study is a randomized, double-blinded, placebo-controlled, cross-over study, which will investigate the acute effects of the gut-derived hormone glucagon-like peptide 2 (GLP-2) on cholecystokinin (CCK)-induced gallbladder…
- Trial name
- NCT04651868
- Testing
- GLP-2, CCK
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Congenital Hyperinsulinism
GLP-1 Receptor Expression in CHI
The primary objective is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of CHI patients.
- Trial name
- GLP-1-CHI (NCT03768518)
- Testing
- 68Ga-exendin-4 PET/CT
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of…
- Conditions
- Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD)
- Trial name
- NCT07073053
- Testing
- Semaglutide 1.0 mg, Semaglutide 0.5 mg
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Kidney Disease, Chronic, Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population.
- Conditions
- Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
- Trial name
- GUARD-1 (NCT07017270)
- Testing
- Semaglutide Pen
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Unity Health Toronto
Hyperglycemia Drug Induced
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib
REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling.
- Trial name
- NCT04253223
- Testing
- REMD-477
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Steatosis of Liver
Liver Fat and Glucagon Resistance
One in four adults worldwide have too much fat stored in the liver which is known as metabolic associated steatotic liver disease (MASLD). This was previously known as non- alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT06154096
- Testing
- Acute glucagon infusion
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Glucagon Resistance in Patients With NAFLD
The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Glucose Metabolism Disorders
- Trial name
- NCT04042142
- Testing
- glucagon
- Where
- Denmark
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Women With Fertility Disorder
Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization
The success of in vitro fertilization is based mainly on uterine implantation embryo. An excessive uterine contractility may interfere with implantation by a movement of the embryo in the uterus.
- Trial name
- NCT01674283
- Testing
- Glucagon
- Where
- Canada
- Sponsor
- Clinique Ovo
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes
Consumption of nutritional supplements with low glycemic carbohydrates induce favorable glycemic responses in subjects with type 2 diabetes.
- Trial name
- NCT03829800
- Testing
- Ensure® Abbott Nutrition, Glucerna® Abbott Nutrition, Diasip® Nutricia Advanced
- Volunteers
- 23 people
- Sponsor
- Universidad del Zulia
Alcohol Dependence, in Remission, Addiction, Alcohol
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs.
- Trial name
- EXALT (NCT03232112)
- Testing
- Exenatide 2 MG Injection, BD PosiFlush (saline)
- Where
- Denmark
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Anders Fink-Jensen, MD, DMSci